CL2014003243A1 - Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar. - Google Patents

Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar.

Info

Publication number
CL2014003243A1
CL2014003243A1 CL2014003243A CL2014003243A CL2014003243A1 CL 2014003243 A1 CL2014003243 A1 CL 2014003243A1 CL 2014003243 A CL2014003243 A CL 2014003243A CL 2014003243 A CL2014003243 A CL 2014003243A CL 2014003243 A1 CL2014003243 A1 CL 2014003243A1
Authority
CL
Chile
Prior art keywords
alkyltriazole
lpar
antagonists
compounds
pulmonary fibrosis
Prior art date
Application number
CL2014003243A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Deems Gabriel
Yimin Qian
Achyutharao Sidduri
Matthew Michael Hamilto0N
Matthew C Lucas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003243(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2014003243A1 publication Critical patent/CL2014003243A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CL2014003243A 2012-06-20 2014-11-28 Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar. CL2014003243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20

Publications (1)

Publication Number Publication Date
CL2014003243A1 true CL2014003243A1 (es) 2015-03-20

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003243A CL2014003243A1 (es) 2012-06-20 2014-11-28 Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar.

Country Status (22)

Country Link
US (1) US9321738B2 (cg-RX-API-DMAC7.html)
EP (1) EP2864300A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015520202A (cg-RX-API-DMAC7.html)
KR (1) KR20150021057A (cg-RX-API-DMAC7.html)
CN (1) CN104411692A (cg-RX-API-DMAC7.html)
AU (1) AU2013279512A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014030685A2 (cg-RX-API-DMAC7.html)
CA (1) CA2869541A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014003243A1 (cg-RX-API-DMAC7.html)
CO (1) CO7131358A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140525A (cg-RX-API-DMAC7.html)
EA (1) EA201492285A1 (cg-RX-API-DMAC7.html)
HK (1) HK1206342A1 (cg-RX-API-DMAC7.html)
IL (1) IL236088A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN09348A (cg-RX-API-DMAC7.html)
MA (1) MA37764A1 (cg-RX-API-DMAC7.html)
MX (1) MX2014014710A (cg-RX-API-DMAC7.html)
PE (1) PE20142448A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014502789A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201407220YA (cg-RX-API-DMAC7.html)
UA (1) UA109868C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013189864A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
UA110310C2 (uk) * 2012-06-20 2015-12-10 Ф. Хоффманн-Ля Рош Аг Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
KR102090231B1 (ko) 2013-03-15 2020-03-17 에피젠 바이오싸이언시즈, 아이엔씨. 질환의 치료에 유용한 헤테로환식 화합물
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
EP3728222B1 (en) 2017-12-19 2023-03-29 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
JP7256807B2 (ja) * 2017-12-19 2023-04-12 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール
WO2019126103A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
CN111699180B (zh) 2017-12-19 2024-11-29 百时美施贵宝公司 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸
CN112521368B (zh) * 2017-12-19 2023-12-05 百时美施贵宝公司 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸
ES2943661T3 (es) 2017-12-19 2023-06-15 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos pirazol-O-ligados como antagonistas de LPA
TW201927778A (zh) 2017-12-19 2019-07-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸三唑唑類
JP7301840B2 (ja) 2017-12-19 2023-07-03 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
TW202017918A (zh) * 2017-12-19 2020-05-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸三唑吖
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
CN117024420A (zh) * 2017-12-29 2023-11-10 生物马林药物股份有限公司 用于疾病治疗的乙醇酸氧化酶抑制剂
ES2948793T3 (es) * 2018-09-18 2023-09-19 Bristol Myers Squibb Co Acidos cicloheptílicos como antagonistas de LPA
US12428430B2 (en) 2018-09-18 2025-09-30 Bristol-Myers Squibb Company Oxabicyclo acids as LPA antagonists
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
EP4058144A1 (en) * 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
CA3185689A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4337641A1 (en) 2021-05-11 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
EP4337654A1 (en) * 2021-05-13 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
EP4444707A1 (en) 2021-12-08 2024-10-16 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
BR112013014019A2 (pt) 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013025733A1 (en) * 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
KR20150021057A (ko) 2015-02-27
CA2869541A1 (en) 2013-12-27
MX2014014710A (es) 2015-03-04
PH12014502789A1 (en) 2015-02-09
PE20142448A1 (es) 2015-01-28
CO7131358A2 (es) 2014-12-01
IL236088A0 (en) 2015-02-01
US20150133511A1 (en) 2015-05-14
BR112014030685A2 (pt) 2017-06-27
EA201492285A1 (ru) 2015-04-30
JP2015520202A (ja) 2015-07-16
HK1206342A1 (en) 2016-01-08
MA37764A1 (fr) 2016-01-29
UA109868C2 (ru) 2015-10-12
CN104411692A (zh) 2015-03-11
WO2013189864A1 (en) 2013-12-27
IN2014DN09348A (cg-RX-API-DMAC7.html) 2015-07-17
AU2013279512A1 (en) 2014-10-16
EP2864300A1 (en) 2015-04-29
CR20140525A (es) 2015-01-12
SG11201407220YA (en) 2014-12-30
US9321738B2 (en) 2016-04-26

Similar Documents

Publication Publication Date Title
CL2014003243A1 (es) Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar.
CL2014003241A1 (es) Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar.
CL2014003242A1 (es) Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra la fibrosis pulmonar.
IL277652A (en) Stable aqueous formulations of adlimumab
IL230913A0 (en) Lysophosphatidic acid receptor antagonists
EP2903509A4 (en) PORTABLE HEART MONITOR
DK2882850T3 (da) System for preparation of adipose-derived stem cells
CO7061086A2 (es) Combinaciones de compuestos activos
EP2925325A4 (en) STABILIZED FORMULATION OF PEMETREXED
CL2015001399A1 (es) Composiciones detergentes acuosas de estructura polimérica.
CO6970595A2 (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
ZA201600753B (en) Amide derivatives as lysophosphatidic acid receptor antagonists
LT2782602T (lt) Nukleotidas dims0-150, skirtas lėtinio aktyvaus opinio kolito gydymui
IL237380A (en) Ethylene derivatives as modulators of mglur5 receptor activity
CR20140343A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
PL2823052T3 (pl) Kompatybilna substancja rozpuszczona - ektoina, jak również jej pochodne do stabilizacji enzymów
ZA201500979B (en) Electrochemical generation of chlorinated urea derivatives
IL237217A0 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
IL237116A (en) Ethinyl derivatives as modulators of mglur5 receptor activity
IL233939B (en) Liquid formulations of hypoglycemic sulfonamides
FR2989199B1 (fr) Adaptateur electriquement actif
GB201419901D0 (en) Improvements relating to hypochlorous acid solutions
EP2939661A4 (en) NOVEL MICROGRANULAR FORMULATION
FR2993559B1 (fr) Procede de preparation de composes diacides
FI20125274L (fi) Levuliinihapon valmistus